© 2022 MJH Life Sciences™ and Managed Healthcare Executive. All rights reserved.
Drug costs
Specialty Pharmacy Controls Limit Patient Access, Fein and Long Explain: 2022 Asembia Specialty Pharmacy Summit
May 04, 2022
In their general session, Adam J. Fein, PhD of Drug Channels Institute, and Doug Long of IQVIA reviewed the current specialty pharmacy space, ongoing trends and future expectations.
ICER: Cosela Doesn’t Meet Health Benefit-Price Benchmark
March 17, 2022
ICER also reviewed, plinabulin, which is development chemotherapy-induced neutropenia (CIN) and would achieve common thresholds for cost-effectiveness if priced between $1,100 and $1,600 per dose.
AHIP Experts Turn an Eye to the Post-Pandemic World
February 23, 2022
During the state of the industry webinar, AHIP experts reviewed policies and solutions to improve affordable access to care and shape healthcare in the post-pandemic world.
Study: Patients Face Access Restrictions for Cell and Gene Therapies
November 10, 2021
The high cost and limited clinical evidence for cell and gene therapies have led U.S. health plans and countries outside the United States to limit access.
States Tackle Drug Pricing
September 07, 2021
For an assortment of reasons, the federal government hasn’t taken any action on regulating drug prices, so a handful of states have taken matters into their own hands.
Rituximab Biosimilars Produce Big Cost Savings, are Effective
September 07, 2021
A large Netherlands study demonstrated that rituximab biosimilars (R-biosimilars) produced a 43% reduction in annual costs. In addition, three-year overall survival did not differ between diffuse large B-cell lymphoma (DLBCL) and those receiving rituximab, according to the researchers.
CBO Updates Model for Assessing Policy Changes on Drug Innovation
August 26, 2021
The new model indicates a small initial impact on new drugs coming to the market, but an impact that grows over time.
ICER Updates Assessment of Hereditary Angioedema Therapies
August 24, 2021
ICER calculations using real-world data would result in major price cuts of three therapies — Takhzyro, Haegarda, and Cinryze — if they were to meet commonly used cost-effective thresholds.
The Generic, Biosimilar Medicine Industry Today and What it Can Become in The Next Decade
July 14, 2021
International Generic and Biosimilar Medicines Association recently released the report, "A Vision for the Global Generic and Biosimilar Medicines Industry,” covering the current global Generic and Biosimilar medicine industry, and released a vision of what the market will be in 2030 and how to achieve it.
Generic Drug Price Tags: Too High. And Too Low. Competition Can Help Create an In-Between.
July 13, 2021
Low prices and some gaming of regulations can drive out competitors and create monopolies that allow generic makers to jack up their prices. Experience has shown that it often takes multiple generics to achieve the promised-for downward pressure on prices.